The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
ZYME · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | EBS | SLN | ZYME | TXMD |
|---|---|---|---|---|
| Moat Score (0–100) | 36 (highest) | 36 (highest) | 36 (highest) | 36 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 15 | 27 | 60 (highest) | 48 |
| Pricing power | 68 | 75 | — | 80 (highest) |
| Returns on capital | 11 (highest) | 0 | 6 | 0 |
| Balance-sheet safety | 29 | 55 (highest) | 55 (highest) | 28 |
| Capital allocation | 57 (highest) | 24 | 24 | 24 |
| No price data | No price data | No price data | No price data | |
| Market cap | $378M | $1.6B | $1.7B | $23.8M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |